Oncology

The next generation in real-time PCR Technology.

PrimeraDx patented STAR technology represents the next generation in real-time PCR technology. The STAR technology uses sequential sampling of PCR product and capillary electrophoresis detection to generate quantitative results with the ability to accurately measure up to 60 analytes in a single sample.

Development of the STAR technology has led to breakthroughs in assay automation, integrated assay controls and detection optics. These breakthroughs combined with our expertise in multiplexed assay development are embodied in the ICE System, a proprietary bench-top clinical instrument system and novel assays in infectious disease and cancer based on the STAR technology.

Our Mission

Multiplexed quantitative and qualitative assays are becoming increasingly important in patient management because they provide more information about disease while reducing lab costs. The STAR technology is uniquely positioned to address the unmet needs currently impacting infectious disease and cancer diagnostics by providing the first technology capable of multiplexing with true quantification.

PrimeraDx is currently evaluating biomarker opportunities in the diagnosis, staging, prognosis and directing patient therapy areas of oncology.